CIHRT Exhibit P-2908 Page 1

Estrogen Receptor/Progesterone Receptor Testing

ient Name	Phone Number MCP #	CWHC# Path.#	ER Status	PR Status	Doctor	Tamoxifen	Ехр	Comments
		S-3801/02	<20%+ve	<10% +ve		No		CONTROL OF THE SECOND
		[S-1281-99	1 <10% +ve	1			May-01	
		IS-3206/98	<5% +Ve	<5% +ve		Yes	n mangari birang Pangari mbirang sa	
		IS-3645/03	<10% +ve	<10% +ve		No		
		S-0219/99	<10% +ve	<10% +ve		No	Dec-01	
		S-1804-04	<20% +ve	<20% +ve		Letrozole	in politica de la composition de la co	
		[5-3822-04	<5% +ve	<%5+ve		No		1
		[S-3035/02	20% weak +ve	20% Stong ave		No	Mar-03	THE THE TAXABLE SERVICE SERVICES SERVIC
		S-1998/00	0% +ve	0% +ve		No		
		[S-1794/02	30-40% weak	(/%+∀e		No		
		IS-1109/03	<5% +ve	<15% 4V8		Yes	June 2005	The state of the s
		<u>[S-4169/99</u>	<5% +ve	<5% +∀6		No	Sept. 2004	1
		IS-4114-98	0% +ve			707	??Deceased	
		S-2289/01	<5% +ve	95% +ve		Yes		
		L IS-1848-05	<5% +va	50% +ve		777		
		IS-2143/03	<5% +VE	<20% +40		Letrozole	Jan-05	
		S-1666/00	<10% +ve	< 10% +7%		No		
		[S-5204-98	5-10%+ve	50-60% +ve		Yes		
		15-439/02	<5% +ve	<5% +VB		No	Jacob Birthing British	
		S-2392/03	<5% +VE	<5% 4Ve		No		
		[S-4613-99	<10% +ve	222		777	Dec.2001	
		S-561-00	<5% +V6	<5% +ve		No l		Followed By Dr.
		S-0481/03	<5% +ve	<5% +VB		No I	Sept. 2004	
		<u> </u>	<5% +ve	<5% +Ve		No .		
		S-2966/99	<u>l Neu</u>	Neg		Yes	Jun-00	
		<u>[\$-4455-99</u>	<5% +ve	<5% +ve		227		
		S-2272/01	<5°% +v€	<5% FVB		72		
		S-3411/02	<5% +ve	<5% +ve		l Ao l		
		S-1339/02	<5% +ve	<5% +ve		No	PORTOR TO POSTOR OUR PROPERTY (A PARTY)	
		S-702-98	<10% +ve	201		222	Apr-00	
		S-2154/03 S-2550-97	<25% 4V8	<5% +Ve		No.		??Primary Unknown
		15-2550-97	Neg	Neg		722		
		S-1948-00	<10% 448	50% +ve		Yes		
		S-1531-02 S-1602/03	25% 476	<5% +ve		No.	-	
		15-1002/03 15-5396/98	<30% +ve	<30 +ve		Yes	Market Special	
		[2-1640/03 [2-1540/88	()%, +We	CPa +vg		L No		
			<5% +ve	<5% +76		777	Testes de la responsación de la companya della companya de la companya della comp	??? Dx: Lymphoma not Breast ca
		S-1830/00 S-2466/00	Neg	Neg		No I	or marketing a second residence of the	
		15-2481-98	20% weak +ve 25% +ve	20% +ve		77		
		15-2401-95 	30% +ye	80% +ve		Yes 1	Apr-03	
		15-1259700 15-2190/02		100 -Ve		Yes L		
			0°% +V6	70% +V8		Yes		Stopped Tamoxifen & Refused Arimide
		IS-0328/00	1-5% +ve	70-80% +ve				
		10-10-0010	10% +ve	10% ive		No I		
		[5-1820/98	_LNeg	Neg [No I		

CIHRT Exhibit P-2908 Page 2

Estrogen Receptor/Progesterone Receptor Testing

TS-4454/98	30-40% weak +ve	1 30-40% +ve	Yes		
1 \$-3571-04	1 <10% +ve	60% +ve	227		**************************************
1 \$-3195/01	1 0% +ve	0% +ve	No.	oner sur inneren en e	
S-3170-00	10% +ve	80% +ve	Yes		-
TS-4888/03	\$5% 4Ve	50% +ve	Yes		
(S-2824/00	0% +ve	0% +ve	blo		
5-1891/00	7% +ve	1 0% +ve	A printing residence of the second second	ner en en france en	
1 8-3322 04	<10% +ve	<10% +ve			
\$-1029-98	0°6 +ve	0%+ve	Ves	·····	······································
5-92-04	75% 4V8	10% +ve	***************************************		***
15.2626.98	0% +ve	<5% +Ve	Company of the Compan		
S-2626-96 S-4512/02	<5% +ve	30% +ve	Yes	**************************************	
3-4060-97	Neg	7777		7?Deceased	
5-1519/99	0% +ve	0% +ve	And the second s		
15.3395/02	₹10% ÷ve	<10% +ve	777		
S-3395/02 S-0149/04	5% +ve	35% +ve	27.7	Feb. 2004	<u> </u>
S-3472/98	1.25%	1-25%	772	reu, zuu4	
S-876-99	25-35% +ve	40-45% +ve	and the state of t		
5-24 91/01	<5% +V8	<5% +V6	ten region in the control of the con		·
15.3019/02	Neg	Neg	No.		-
S-3918/02 S-678-02	<5% +ve	<5% +ve	7/27	 Jun-02	
S-257/01	Neg	Neg (the assertance of the second s	JUII-UE	
S-1958/98	Neg	50-60% weak +ve	272		
S-2841/99	Nec	Neg Neg			
6-2012/01	Neg	60%	The second secon		
G-3382/00	Neg	90%	Yes		.
S-1407-99	15-20% +ve	30-40% +ve	Yes		-
S-4022-04	<5% +ve	<5% +ve	272		
S-5200-98	And an increase of the continues of the		702		
S-3811/00	0% +ve Neg	25-30% +ve	77.77		
G-4478/98		Neg	Water State Comment		
S-2913-04	Neg Man	Neg			
5-2913-04 5-3187/01	Neg	Neg	Andrew Street,		
S-3187/01 S-1723/03	40% -ve	10-30%	Yes	2003	
IS-1723/03 IS-38127/01	Neg	Neg			
S-1590/98	Neg	- Neg			
S-2137-00	1-5%	Neg	and the second s	Dec. 1998	
5-2157-00 S-1498/01	<10% +ve	75% +78	Yes	Dec. 2002	
	25% 4V6	>75% +ve]	522	May-03	
[5-2137-00 & 3528-00]	Neg/<10% +ve	Neg<10% +ve	No.	Jan-03	
S-1988/98	Neg	AGQ.	No.		
E-3906/01			Ves	······································	
S-0428/04	<5% +ve]	50% ave	manufacture and the second		
5-3034/03	10% +ve	<10% +ve	NC		
S-0642/99	Neg 1	Neg [NET THE STATE OF T		
S-1006/00	10% +ve	10% eve	No		
S-3668/03	5% 4Ve 1	20% +ve	Yes		

CIHRT Exhibit P-2908 Page 3

Estrogen Receptor/Progesterone Receptor Testing

	1 <10% +ve	<5% - Ve		777		
S-0548/99	5-10% +ve	5-10% +ve		777		
S-1915/00	<20% ave	<10% +ve		Yes	Karangan sanga	
S-547-01	<5% +ve	7.7		???	Aug-01	
\$-3809/00	Neg	Neg		777		
\$-3073/99	Neg	Neo		No		
(S-1927-00	20%+4/6	20% +ve		777	(A. S. 1011 - C. 1017 - C. 1013 - C. 1017 - C.	And the second of the second o
S-4472:37	Minimaliy +ve	Moderately +ve		222		
S-5448/98	Neg	10-15% +ve		Yes		
S-2008-05] <10% +ve	80% +ve		777		The second secon
S-2764/00	<10% +ve	<10% H/6		No	10-17-17-17-100	The state of the s
S-31/20/98	Neg	Neg		No		
S-875-99	5% +ve	75% +ve	Le	trozole		El Company of the Com

Comments: There are 105 patients on this list of which: 27 have been treated

13 deceased and not treated

14 positive, not treated and not deceased therfore 51 patients that need retesting